EXAS
$79.02
Exact Sciences Cor
($4.91)
(5.85%)
EXAS
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.37)
Revenue:  $227.95 Mil
Tuesday
Jan 28
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EXAS reports earnings?
Beat
Meet
Miss

Where is EXAS's stock price going from here?
Up
Flat
Down
Stock chart of EXAS
Analysts
Summary of analysts' recommendations for EXAS
Score
Grade
Pivots
Resistance
$88.41
$86.45
$82.74

$80.78

Support
$77.07
$75.11
$71.40
Tweet
Growth
Description
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.
Peers
Alexion PharmaceuticalsIncyteCharles River Laboratories InternationalExelixisCoherus BiosciencesLuminex